Scotiabank lowered the firm’s price target on Kura Oncology (KURA) to $10 from $18 and keeps a Sector Perform rating on the shares. The firm adjusted its price target on the stock based on its revised market share estimates for revumenib in relapsed/refractory KMT2Ar acute lymphoblastic leukemia and front-line acute leukemia treatment settings, the analyst tells investors.
Stay Ahead of the Market:
- Discover outperforming stocks and invest smarter with Top Smart Score Stocks
- Filter, analyze, and streamline your search for investment opportunities using Tipranks' Stock Screener
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on KURA:
- Kura Oncology Announces Leadership Changes and Appointments
- Kura Oncology CMO Stephen Dale steps down, Mollie Leoni succeeds
- Kura Oncology, Kyowa Kirin report data on KOMET-007 at ASH meeting
- Kura Oncology holds a pharmaceutical update conference call
- Kura Oncology management to meet with Cantor Fitzgerald